highly speculative with 20+++ bagger potential:
Viropro was awarded a contract by Spectrum (SPPI) to develop a biosimilar for Roche's $5.6B Rituxan.
Viropro is a holding company that is purchasing crucial pieces in their attempt to become a one stop shop for biotechs wishing to develop biosimilars.
VPRO.pk jumped over 2000% in January, on news of the SPPI contract, but has drifted back to around 3cents. Last Friday it closed up ~42%
It is worth a look for one's high spec' funds. Be prepared for intense volatility.
AEZS seems quite undervalued, particularly in relation to KERX.
The AEZS pipe is most impressive .... Seems like a stable safe pick.
AEN is worthy of a look, particularly for those interested in the potential of Alzheimer's market. AEN's lead product is a zinc-cysteine "Rx medical food" with great promise in halting the progression of Alzheimer's.
As for Fibrocell ... the PDUFA on June 22nd ... a lucky day for my family!